Rationale and Design of the Double-Blind, Randomized, Placebo-Controlled Multicenter Trial on Efficacy of Early Initiation of Eplerenone Treatment in Patients with Acute Heart Failure (EARLIER)
Masafumi Kitakaze(Hanwa Memorial Hospital), Satoshi Yasuda(Tohoku University), Kuniya Asai(Nippon Medical School), Kazuo Kimura(Yokohama City University Medical Center), Akiko Kada(National Hospital Organization), Atsushi Hirayakma(Nihon University), Youichi Kobayashi, Shin‐ichi Momomura, Yutaro Nishi(St. Luke's International Hospital), Masanori Asakura(National Cerebral and Cardiovascular Center), Akihisa Hanatani(Osaka City University), Takahisa Yamada(Osaka Prefectural Medical Center), Yoshihiko Saito(National Archives and Records Administration), Haruko Yamamoto(National Cerebral and Cardiovascular Center), Hiroyuki Uesaka(National Cerebral and Cardiovascular Center), Yoshihisa Nakagawa(Shiga University of Medical Science), Tsutomu Yoshikawa(Sakakibara Hospital), Ken–ichi Hirata(Kobe University), Akira Yamashina(Tokyo Medical University), Yasuhiro Satoh(Osaka Prefectural Medical Center)
Cited by 13
Related Papers
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: Metalloproteinase inhibitors as a new therapy
|Nature Medicine|2002|722
JCS 2018 Guideline on Diagnosis and Treatment of Acute Coronary Syndrome
|Circulation Journal|2019|582
Brachial-Ankle Pulse Wave Velocity and the Risk Prediction of Cardiovascular Disease
|Hypertension|2017|538